Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2017

01-05-2017 | Original Article

Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population

Authors: Tan Tan, Kai Zhang, Wenjun Chen Sun

Published in: Breast Cancer | Issue 3/2017

Login to get access

Abstract

Background

The objective of this study was to investigate whether the genetic polymorphism rs12665607 of ESR1, rs10995190 of ZNF365, rs3817198 of LSP1 and rs17001868 of SGSM3/MKL1 are associated with the development of breast cancer (BC) in the Chinese women.

Methods

The 4 SNPs were genotyped for 453 female BC patients and 750 controls. The differences of genotype and allele distributions between patients and controls were evaluated using the Chi-square test. The comparison of SGSM3 expression in the tumor and the adjacent normal breast tissues was carried out by the Student’s t test. One-way ANOVA test was used to analyze the relationship between genotypes of rs17001868 and the tissue expression of SGSM3.

Results

Patients were found to have significantly higher allele T of rs12665607 and allele C of rs17001868 than that of the controls (35.2 % vs. 29.6 %, p = 0.004 for rs12665607; 23.1 % vs. 19.1 %, p = 0.02 for rs17001868). The OR values were 1.29 for rs12665607 and 1.27 for rs17001868, respectively. The mean expression level of SGSM3 was significantly lower in BC tumors than in the adjacent normal tissues (0.0082 ± 0.0038 vs. 0.0134 ± 0.0078; p < 0.001). Patients with genotype CC were found to have a remarkably lower SGSM3 expression in the tumors than those with genotype AA (p = 0.007).

Conclusions

ESR1 gene and the SGSM3 gene are associated with the risk of BC in Chinese population. Besides, rs17001868 may be a putative functional variant that can affect the expression of SGSM3 in patients with BC. With the OR ranging from 1.27 to 1.29, variants of these 2 genes can only explain limited variance of BC. Further investigations into the functional role of the susceptible genes would be helpful to clarify the etiology of BC.
Literature
1.
Curado MP. Breast cancer in the world: incidence and mortality. Salud Publica Mex. 2011;53(5):372–84.PubMed
2.
Khanna R, Bhanegaonkar A, Colsher P, Madhavan SS, Halverson J. Breast cancer screening, incidence, and mortality in West Virginia. W Va Med J. 2009;105:Spec No: 24–32.
3.
Njor S, Nystrom L, Moss S, Paci E, Broeders M, Segnan N, et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33–41.CrossRefPubMed
4.
Benson JR, Purushotham A. Trends in breast cancer incidence, survival, and mortality. Lancet. 2000;356(9229):591 (author reply 593).CrossRefPubMed
5.
Berkemeyer S, Lemke D, Hense HW. Incidence and mortality trends in German women with breast cancer using age, period and cohort 1999–2008. PLoS One. 2016;11(3):e0150723.CrossRefPubMedPubMedCentral
6.
Brewster D, Everington D, Harkness E, Gould A, Warner J, Dewar JA, et al. Incidence of and mortality from breast cancer since introduction of screening. Scottish figures show higher incidence and similar mortality. BMJ. 1996;312(7031):639–40.CrossRefPubMedPubMedCentral
7.
Dite GS, Stone J, Chiarelli AM, Giles GG, English DR, Cawson JC, et al. Are genetic and environmental components of variance in mammographic density measures that predict breast cancer risk independent of within-twin pair differences in body mass index? Breast Cancer Res Treat. 2012;131(2):553–9.CrossRefPubMed
8.
Reeves GK, Pirie K, Green J, Bull D, Beral V. Million women study C: comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012;131(4):930–7.CrossRefPubMed
9.
Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, et al. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci. 2011;102(11):2065–72.CrossRefPubMed
10.
Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, et al. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Bull Cancer. 2014;101(11):E36–40.PubMed
11.
Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, et al. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Breast Cancer Res Treat. 2011;126(1):119–30.CrossRefPubMed
12.
Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. 2011;10(2):199–205.CrossRefPubMed
13.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.CrossRefPubMedPubMedCentral
14.
Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77(4):697–709.CrossRefPubMed
15.
Lee SA, Lee KM, Lee SJ, Yoo KY, Park SK, Noh DY, et al. Antioxidant vitamins intake, ataxia telangiectasia mutated (ATM) genetic polymorphisms, and breast cancer risk. Nutr Cancer. 2010;62(8):1087–94.CrossRefPubMed
16.
Jara L, Gonzalez-Hormazabal P, Cerceno K, Di Capua GA, Reyes JM, Blanco R, et al. Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Breast Cancer Res Treat. 2013;137(2):559–69.CrossRefPubMed
17.
Liang J, Chen P, Hu Z, Shen H, Wang F, Chen L, et al. Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population. Breast Cancer Res Treat. 2010;124(1):237–41.CrossRefPubMed
18.
Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71(2):432–8.CrossRefPubMedPubMedCentral
19.
Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat. 2011;127(3):853–9.CrossRefPubMed
20.
Cai Q, Zhang B, Sung H, Low SK, Kweon SS, Lu W, et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014;46(8):886–90.CrossRefPubMedPubMedCentral
21.
Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44(3):312–8.CrossRefPubMedPubMedCentral
22.
Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870–4.CrossRefPubMedPubMedCentral
23.
Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41(5):579–84.CrossRefPubMedPubMedCentral
24.
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010;42(6):504–7.CrossRefPubMedPubMedCentral
25.
Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009;41(3):324–8.CrossRefPubMedPubMedCentral
26.
Lindstrom S, Thompson DJ, Paterson AD, Li J, Gierach GL, Scott C, et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun. 2014;5:5303.CrossRefPubMedPubMedCentral
27.
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4.CrossRefPubMed
28.
Barzan D, Veldwijk MR, Herskind C, Li Y, Zhang B, Sperk E, et al. Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations. Eur J Hum Genet EJHG. 2013;21(11):1286–92.CrossRefPubMed
29.
Hong Y, Chen XQ, Li JY, Liu C, Shen N, Zhu BB, et al. Current evidence on the association between rs3757318 of C6orf97 and breast cancer risk: a meta-analysis. Asian Pac J Cancer Prev APJCP. 2014;15(19):8051–5.CrossRefPubMed
30.
Stone J, Thompson DJ, Dos Santos Silva I, Scott C, Tamimi RM, Lindstrom S, et al. Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures. Cancer Res. 2015;75(12):2457–67.CrossRefPubMedPubMedCentral
31.
Chen W, Song H, Zhong R, Zhu B, Guo H, Lou J, et al. Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis. Breast Cancer Res Treat. 2013;142(3):637–44.CrossRefPubMed
32.
Zhou L, He N, Feng T, Geng T, Jin T, Chen C. Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China. Am J Cancer Res. 2015;5(8):2467–75.PubMedPubMedCentral
33.
Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61 (361e351-352).CrossRefPubMedPubMedCentral
34.
Nourashrafeddin S, Aarabi M, Modarressi MH, Rahmati M, Nouri M. The evaluation of WBP2NL-Related genes expression in breast cancer. Pathol Oncol Res POR. 2015;21(2):293–300.CrossRefPubMed
35.
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40:930–4.CrossRef
Metadata
Title
Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population
Authors
Tan Tan
Kai Zhang
Wenjun Chen Sun
Publication date
01-05-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0712-5

Other articles of this Issue 3/2017

Breast Cancer 3/2017 Go to the issue

Original Article

The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy

Original Article

Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries

Original Article

Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression

Review Article

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials

Original Article

Breast reconstruction using free medial circumflex artery perforator flaps: intraoperative anatomic study and clinical results

Original Article

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits